Skip to main content

Advertisement

Table 8 Real world trial data comparison

From: Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

  mPFS (mo) mOS (mo) DCR (CR + PR + SD) (%)
SAX real world 7.14 15.5 70.6
Spanish real world 4.4 10.8 65.7
France real world 8.3, 16.4, 72
AXIS 6.5 15.2 69.3